Francesca Gay, MD, PhD

Francesca Gay, MD, PhD, discusses the safety and efficacy findings derived from the phase 3 IsKia trial in patients with newly diagnosed multiple myeloma.

Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in patients with newly diagnosed multiple myeloma.

Francesca Gay, MD, PhD, hematologist, Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, discusses the updated efficacy data from the FORTE trial of patients with newly-diagnosed multiple myeloma.